RGC Quote, Financials, Valuation and Earnings

HUTCHMED (China) has a net margin of -- compared to Regencell Bioscience Holdings's net margin of --. Regencell Bioscience Holdings's return on equity of -- beat HUTCHMED (China)'s return on equity of 4.99%.

Regencell Bioscience Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand HUTCHMED (China) has an analysts' consensus of $26.36 which suggests that it could grow by 91.6%. Given that HUTCHMED (China) has higher upside potential than Regencell Bioscience Holdings, analysts believe HUTCHMED (China) is more attractive than Regencell Bioscience Holdings.

Regencell Bioscience Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison HUTCHMED (China) has a beta of 0.658, suggesting its less volatile than the S&P 500 by 34.171%.

Regencell Bioscience Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HUTCHMED (China) offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regencell Bioscience Holdings pays -- of its earnings as a dividend. HUTCHMED (China) pays out -- of its earnings as a dividend.

Regencell Bioscience Holdings quarterly revenues are --, which are smaller than HUTCHMED (China) quarterly revenues of --. Regencell Bioscience Holdings's net income of -- is lower than HUTCHMED (China)'s net income of --. Notably, Regencell Bioscience Holdings's price-to-earnings ratio is -- while HUTCHMED (China)'s PE ratio is 68.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regencell Bioscience Holdings is -- versus 3.81x for HUTCHMED (China). Usually stocks with elevated PS ratios are considered overvalued.

Hong Kong Pharma Digital Technology Holdings has a net margin of -- compared to Regencell Bioscience Holdings's net margin of --. Regencell Bioscience Holdings's return on equity of -- beat Hong Kong Pharma Digital Technology Holdings's return on equity of --.

Regencell Bioscience Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Hong Kong Pharma Digital Technology Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that Regencell Bioscience Holdings has higher upside potential than Hong Kong Pharma Digital Technology Holdings, analysts believe Regencell Bioscience Holdings is more attractive than Hong Kong Pharma Digital Technology Holdings.

Regencell Bioscience Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Hong Kong Pharma Digital Technology Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Regencell Bioscience Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hong Kong Pharma Digital Technology Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regencell Bioscience Holdings pays -- of its earnings as a dividend. Hong Kong Pharma Digital Technology Holdings pays out -- of its earnings as a dividend.

Regencell Bioscience Holdings quarterly revenues are --, which are smaller than Hong Kong Pharma Digital Technology Holdings quarterly revenues of --. Regencell Bioscience Holdings's net income of -- is lower than Hong Kong Pharma Digital Technology Holdings's net income of --. Notably, Regencell Bioscience Holdings's price-to-earnings ratio is -- while Hong Kong Pharma Digital Technology Holdings's PE ratio is 5.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regencell Bioscience Holdings is -- versus 0.48x for Hong Kong Pharma Digital Technology Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Prenetics Global has a net margin of -- compared to Regencell Bioscience Holdings's net margin of -137.21%. Regencell Bioscience Holdings's return on equity of -- beat Prenetics Global's return on equity of -23.16%.

Regencell Bioscience Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Prenetics Global has an analysts' consensus of $13.00 which suggests that it could grow by 224.19%. Given that Prenetics Global has higher upside potential than Regencell Bioscience Holdings, analysts believe Prenetics Global is more attractive than Regencell Bioscience Holdings.

Regencell Bioscience Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Prenetics Global has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Regencell Bioscience Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prenetics Global offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regencell Bioscience Holdings pays -- of its earnings as a dividend. Prenetics Global pays out -- of its earnings as a dividend.

Regencell Bioscience Holdings quarterly revenues are --, which are smaller than Prenetics Global quarterly revenues of $7.8M. Regencell Bioscience Holdings's net income of -- is lower than Prenetics Global's net income of -$10.7M. Notably, Regencell Bioscience Holdings's price-to-earnings ratio is -- while Prenetics Global's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regencell Bioscience Holdings is -- versus 1.93x for Prenetics Global. Usually stocks with elevated PS ratios are considered overvalued.

Sino Biopharmaceutical has a net margin of -- compared to Regencell Bioscience Holdings's net margin of --. Regencell Bioscience Holdings's return on equity of -- beat Sino Biopharmaceutical's return on equity of 8.57%.

Regencell Bioscience Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Sino Biopharmaceutical has an analysts' consensus of -- which suggests that it could fall by --. Given that Regencell Bioscience Holdings has higher upside potential than Sino Biopharmaceutical, analysts believe Regencell Bioscience Holdings is more attractive than Sino Biopharmaceutical.

Regencell Bioscience Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sino Biopharmaceutical has a beta of 0.536, suggesting its less volatile than the S&P 500 by 46.434%.

Regencell Bioscience Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sino Biopharmaceutical offers a yield of 2.19% to investors and pays a quarterly dividend of $0.00 per share. Regencell Bioscience Holdings pays -- of its earnings as a dividend. Sino Biopharmaceutical pays out -- of its earnings as a dividend.

Regencell Bioscience Holdings quarterly revenues are --, which are smaller than Sino Biopharmaceutical quarterly revenues of --. Regencell Bioscience Holdings's net income of -- is lower than Sino Biopharmaceutical's net income of --. Notably, Regencell Bioscience Holdings's price-to-earnings ratio is -- while Sino Biopharmaceutical's PE ratio is 17.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regencell Bioscience Holdings is -- versus 2.13x for Sino Biopharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.